Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy

被引：12
作者：
Banach, Monika [1 ,2 ]
Borowicz, Kinga K. [2 ]
Czuczwar, Stanislaw J. [1 ,3 ]
机构：
[1] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland
[2] Med Univ Lublin, Dept Pathophysiol, Independent Unit Expt Neuropathophysiol, PL-20090 Lublin, Poland
[3] Inst Rural Hlth, Dept Physiopathol, PL-20092 Lublin, Poland
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 04期
关键词：
epilepsy; eslicarbazepine; eslicarbazepine acetate; partial seizures; PARTIAL-ONSET SEIZURES; STEADY-STATE PHARMACOKINETICS; MAXIMAL ELECTROSHOCK TEST; GATED SODIUM-CHANNELS; OPEN-LABEL EXTENSION; ACETATE BIA 2-093; LONG-TERM SAFETY; ANTIEPILEPTIC DRUGS; ISOBOLOGRAPHIC ANALYSIS; HEALTHY-SUBJECTS;
D O I：
10.1517/17425255.2015.1021686
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Introduction: Eslicarbazepine acetate (ESL) is a novel antiepileptic drug registered as the adjunctive treatment of partial-onset seizures in adults. As a third-generation medication, ESL is believed to have favorable efficacy/safety profile and pharmacokinetic properties in comparison with related drugs (carbamazepine and oxcarbazepine). Areas covered: The aim of the paper was to evaluate pharmacodynamic and pharmacokinetic properties of ESL with aspect to epilepsy treatment. The review of the scientific literature was based on the PubMed database, Clinical Trials, FDA and European Medicines Agency websites to elicit current information on drug metabolism, mechanism of action and efficacy/safety profile. Expert opinion: Results of clinical trials indicate that ESL possessed a favorable profile of anticonvulsant efficacy and tolerability as an add-on therapy in adult patients at daily doses of 800 and 1200 mg. Pediatric trials are in progress and their results will allow to characterize a role of ESL in the treatment of epilepsy in children.
引用
收藏
页码：639 / 648
页数：10
相关论文
共 64 条
  • [1] Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects
    Almeida, L
    Falcao, A
    Maia, J
    Mazur, D
    Gellert, M
    Soares-da-Silva, P
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) : 1062 - 1066
  • [2] Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects
    Almeida, L.
    Nunes, T.
    Sicard, E.
    Rocha, J. -F.
    Falcao, A.
    Brunet, J. -S.
    Lefebvre, M.
    Soares-da-Silva, P.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2010, 121 (04): : 257 - 264
  • [3] Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy
    Almeida, Luis
    Minciu, Ioana
    Nunes, Teresa
    Butoianu, Nicolina
    Falcao, Amilcar
    Magureanu, Sandra-Adriana
    Soares-da-Silva, Patricio
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (08) : 966 - 977
  • [4] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Almeida, Luis
    Potgieter, J. Hendrick
    Maia, Joana
    Potgieter, M. Alida
    Mota, Fernando
    Soares-da-Silva, P.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) : 267 - 273
  • [5] Eslicarbazepine acetate (BIA 2-093)
    Almeida, Luis
    Soares-da-Silva, Patricio
    [J]. NEUROTHERAPEUTICS, 2007, 4 (01) : 88 - 96
  • [6] Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels
    Ambósio, AF
    Silva, AP
    Malva, JO
    Soares-da-Silva, P
    Carvalho, AP
    Carvalho, CM
    [J]. BIOCHEMICAL PHARMACOLOGY, 2001, 61 (10) : 1271 - 1275
  • [7] Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons:: A comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093
    Araújo, IM
    Ambrósio, AF
    Leal, EC
    Verdasca, MJ
    Malva, JO
    Soares-Da-Silva, P
    Carvalho, AP
    Carvalho, CM
    [J]. EPILEPSIA, 2004, 45 (12) : 1498 - 1505
  • [8] Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy
    Ben-Menachem, E.
    Gabbai, A. A.
    Hufnagel, A.
    Maia, J.
    Almeida, L.
    Soares-da-Silva, P.
    [J]. EPILEPSY RESEARCH, 2010, 89 (2-3) : 278 - 285
  • [9] Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives
    Benes, J
    Parada, A
    Figueiredo, AA
    Alves, PC
    Freitas, AP
    Learmonth, DA
    Cunha, RA
    Garrett, J
    Soares-da-Silva, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (14) : 2582 - 2587
  • [10] Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
    Bialer, M
    Johannessen, SI
    Kupferberg, HJ
    Levy, RH
    Perucca, E
    Tomson, T
    [J]. EPILEPSY RESEARCH, 2004, 61 (1-3) : 1 - 48
1234567